New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

by Elana GotkineFor patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therap
World medicine December 05,2023
Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

Capivasertib-fulvestrant therapy increases PFS in HR-positive breast cancer

by Elana GotkineFor patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therap
World medicine December 05,2023
Cancer may lurk in 'normal looking' skin

Cancer may lurk in 'normal looking' skin

byUniversity of QueenslandSkin mutation load reflects ultraviolet (UV) exposure. (A) Left: Mutation load of chronic ultraviolet B (UVB)–irradiated mice. Right: Spearman correlation of mutation l
World medicine December 05,2023
Cancer may lurk in 'normal looking' skin

Cancer may lurk in 'normal looking' skin

byUniversity of QueenslandSkin mutation load reflects ultraviolet (UV) exposure. (A) Left: Mutation load of chronic ultraviolet B (UVB)–irradiated mice. Right: Spearman correlation of mutation l
World medicine December 05,2023
Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

byScience China PressPerioperative CA242 changing patterns were defined based on preoperative and postoperative CA242 levels, and longitudinal CA242 trajectories were fitted using repeated CA242
World medicine December 05,2023
Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

Perioperative changing patterns and longitudinal trajectories of CA242 with colorectal cancer prognosis

byScience China PressPerioperative CA242 changing patterns were defined based on preoperative and postoperative CA242 levels, and longitudinal CA242 trajectories were fitted using repeated CA242
World medicine December 05,2023
CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

by Impact Journals LLCKaplan-Meier survival curve of duodenal adenocarcinoma patients with elevated CA 19-9 (green) and with normal CEA (blue). Credit:Oncotarget(2023). DOI: 10.18632/oncot
World medicine December 05,2023
CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

CA 19-9 and CEA in prognosis of duodenal adenocarcinoma: A retrospective study

by Impact Journals LLCKaplan-Meier survival curve of duodenal adenocarcinoma patients with elevated CA 19-9 (green) and with normal CEA (blue). Credit:Oncotarget(2023). DOI: 10.18632/oncot
World medicine December 05,2023
BUB1 regulates EGFR signaling by reducing EGFR internalization

BUB1 regulates EGFR signaling by reducing EGFR internalization

by Impact Journals LLCBUB1 inhibitor reduces endocytosis of active EGFR in MDA-MB-231-1833 cells. Credit:Aging(2023). DOI: 10.18632/aging.204820A new research paper titled "Budding un
World medicine December 05,2023
BUB1 regulates EGFR signaling by reducing EGFR internalization

BUB1 regulates EGFR signaling by reducing EGFR internalization

by Impact Journals LLCBUB1 inhibitor reduces endocytosis of active EGFR in MDA-MB-231-1833 cells. Credit:Aging(2023). DOI: 10.18632/aging.204820A new research paper titled "Budding un
World medicine December 05,2023
Axi-cel significantly improves survival in trial patients with early relapsed or refractory large B-cell lymphoma

Axi-cel significantly improves survival in trial patients with early relapsed or refractory large B-cell lymphoma

byUniversity of Texas M. D. Anderson Cancer CenterHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0Patients with early rela
World medicine December 05,2023
Axi-cel significantly improves survival in trial patients with early relapsed or refractory large B-cell lymphoma

Axi-cel significantly improves survival in trial patients with early relapsed or refractory large B-cell lymphoma

byUniversity of Texas M. D. Anderson Cancer CenterHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0Patients with early rela
World medicine December 05,2023
Atezolizumab can induce response in alveolar soft part sarcoma

Atezolizumab can induce response in alveolar soft part sarcoma

by Elana GotkineThe immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the S
World medicine December 05,2023
Atezolizumab can induce response in alveolar soft part sarcoma

Atezolizumab can induce response in alveolar soft part sarcoma

by Elana GotkineThe immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the S
World medicine December 05,2023
Atezolizumab monotherapy beneficial for non-small cell lung cancer ineligible for platinum-based chemo

Atezolizumab monotherapy beneficial for non-small cell lung cancer ineligible for platinum-based chemo

by Elana GotkineFor patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compar
World medicine December 05,2023
Atezolizumab monotherapy beneficial for non-small cell lung cancer ineligible for platinum-based chemo

Atezolizumab monotherapy beneficial for non-small cell lung cancer ineligible for platinum-based chemo

by Elana GotkineFor patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compar
World medicine December 05,2023
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer

ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainHER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refrac
World medicine December 05,2023
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer

ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainHER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refrac
World medicine December 05,2023
AI predicts future pancreatic cancer

AI predicts future pancreatic cancer

byHarvard Medical SchoolTraining and prediction of pancreatic cancer risk from disease trajectories.a, Learning: The general ML workflow starts with partitioning the data into a training s
World medicine December 05,2023
AI predicts future pancreatic cancer

AI predicts future pancreatic cancer

byHarvard Medical SchoolTraining and prediction of pancreatic cancer risk from disease trajectories.a, Learning: The general ML workflow starts with partitioning the data into a training s
World medicine December 05,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com